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Abstract
This issue’s Recently published papers commentary considers the
popular and muddy waters of glycaemic control, stops briefly to
ponder the incidence of pulmonary embolus in acute exacerbations
of chronic obstructive pulmonary disease, promotes novel studies
in the areas of traumatic brain injury and extracorporeal circuits,
and rounds off with a potentially dogma-challenging study in
cardiac arrest.
And the answer is …?
Optimal glycaemic management continues to be the focus of
many authors’ research efforts, with at least seven noteworthy
papers published during the past 2 months. Despite this
burgeoning body of work many controversies remain.
The first study to consider is the so-called NICE-SUGAR
collaboration between the Canadian, Australian and New
Zealand trials groups [1]. An excellent and pragmatic design
was employed, and 6,104 patients were recruited and
randomized to glycaemic targets of 4.5 to 6.0 mmol/l (80 to
110 mg/dl) or <10.0 mmol/l (<180 mg/dl). An evidence-
based feeding guideline was used that favoured enteral
nutrition, and glycaemic monitoring was preferentially
performed by arterial blood analysis. A myriad of end-points
and analyses were performed but the headline result was a
statistically significant higher 90-day mortality in the group
with the 4.5 to 6.0 mmol/l target (27.5% versus 24.9%),
predominantly attributed to cardiovascular causes. The
Kaplan-Meier curves show that the groups separate roughly
between days 20 and 40. The authors’ conclusion rightly
stresses that a universal target of 4.5 to 6.0 mmol/l cannot be
recommended over the target of <10 mmol/l. However, the
explanation for the apparent excess mortality remains highly
speculative, with the authors and many commentators
focusing on the higher incidence of hypoglycaemia in this
group.
To add weight to their argument, the same group added the
data from the above trial to all of the other published trials
and conducted a meta-analysis [2]. Unsurprisingly, given the
patient numbers in the NICE-SUGAR study, that analysis
reached the same conclusion.
However, the story doesn’t end there. The investigators from
Belgium who conducted the original glycaemic control study
have reported another study of their tight control protocol, on
this occasion in a paediatric population [3]. As with their first
trial, the majority (75%) of patients were admitted after
cardiac surgery. They recruited 700 patients and demon-
strated statistically significant improvements in the protocol
group in terms of inflammatory markers, secondary infection
rates (29.2% versus 36.8%) and 30-day mortality (2.3%
versus 5.1%). The incidence of hypoglycaemia was 24.9% in
the protocol group versus 1.5% in the control group. Long-
term developmental follow up is planned to investigate
possible sequelae.
The explanation for the success of this group’s studies
remains contentious. The predominance of elective cardiac
surgical patients and greater use of parenteral nutrition are
often considered, but these lack a clear pathophysiological
basis. Perhaps a more important point is the glycaemic target
in their control group, which was set at <11.9 mmol/l
(<215 mg/dl). Emerging work has suggested that the
threshold for glycaemic toxicity may well be in the 8.0 to
12.0 mmol/l (140 to 215 mg/dl) range and may differ
between tissues.
Indeed, this group have also just reported a very detailed
animal study, further elucidating the pathophysiology of
hyperglycaemia in a rabbit model of 7-day critical illness
secondary to extensive tissue injury [4]. The study identified a
cytopathic and mitochondrial injury that was associated with
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glucose levels of 13.9 to 19.4 mmol/l (250 to 350 mg/dl),
with the liver being the worst affected organ. Myocardium
was also severely affected but skeletal muscle was relatively
spared. Hyperinsulinaemia in the context of normoglycaemia
was of no benefit. Hyperinsulinaemia in the context of
hyperglycaemia significantly worsened the mitochondrial and
tissue injury observed. Toxic products of glycolysis appear to
be responsible for the tissue injury.
Continuing on the glycaemic control theme, Savioli and
colleagues [5] investigated the effects of tight control on
fibrinolysis and the Sequential Organ Failure Score in patients
with severe sepsis or septic shock. This was a small study,
recruiting only 90 patients. Thirty-four of the patients were
found to have inhibition of fibrinolysis, which was associated
with a doubling of 90-day mortality (44% versus 21%). The
patients randomized to tight glycaemic control demonstrated
minor biochemical and overall score benefits, which
manifested only after several days of therapy. Most notable,
however, were the average blood glucose levels in the two
groups, which were about 8.5 mmol/l (153 mg/dl) versus
about 5.8 mmol/l (105 mg/dl). In short, the minimal benefits
identified in the tightly controlled group arguably represent the
minimal differences in glycaemic control between the groups.
Moving onto a very large observational study (66,184 patients),
Bagshaw and colleagues [6] present the results of a database
of average blood glucose level during the first 24 hours of ICU
admission. They divided patients into quartiles of <5.60 mmol/l
(<100 mg/dl), 5.60 to 8.69 mmol/l (100 to 157 mg/dl), 8.69 to
11.79 mmol/l (157 to 121 mg/dl) and >11.79 mmol/l
(>212 mg/dl), and they found hospital mortality rates of 17.5%,
13.9%, 20.3% and 24.4%, respectively.
Overall, what does seem to be emerging is that blood
glucose levels in the critically ill probably do have an optimal
but narrow range, and that perhaps this range is slightly but
significantly higher than the 4.5 to 6.0 mmol/l originally
described.
Finally, on the subject of glycaemic control is a study looking
at iatrogenic hypoglycaemia. One of the purported mecha-
nisms by which tight glycaemic control may confer harm is by
the near universal increase in the incidence of hypoglycaemia.
As with the emerging case for trying to define the optimal
blood glucose range, which probably shifts with patient
condition, defining what level and for what duration hypo-
glycaemia inflicts end organ damage remains undefined. In
order to address this question, an American group has
reported a study interrogating a clinical database of 7,820
patients admitted with acute myocardial infarction. The
database recorded all incidences of hypoglycaemia, defined
as blood glucose below 3.3 mmol/l (<60 mg/dl) together with
administration of insulin. Patients who had one or more
episodes of hypoglycaemia had an in-hospital mortality of
12.7% versus 9.6% in those who did not. However, patients
who received insulin had near identical in-hospital mortality
rates (10.4% in the hypoglycaemic group versus 10.2% in
the group without hypoglycaemia). In contrast, in the patients
who did not receive insulin therapy, the in-hospital mortality
associated with hypoglycaemia was 18.4% versus 9.2% in
those without. Thus, iatrogenic hypoglycaemia does not
appear to be detrimental, whereas spontaneous hypogly-
caemia is at least a marker of severity of illness, if not a contri-
butory factor. What this study does not address is the long-
term neurocognitive outcome of iatrogenic hypoglycaemia.
Why so breathless?
To investigate the proportion of acute exacerbations of
chronic obstructive pulmonary disease that are due to an
acute pulmonary thrombo-embolic event, Rizkallah and
colleagues [7] performed a meta-analysis of the available
literature. The studies that they identified are heterogeneous
and none is without methodological issues, but they found a
surprisingly high prevalence rate in hospitalized patients of
24.7% (95% confidence interval 17.9% to 31.4%). They
describe that pre-imaging probability models had rarely been
used, and in the one study that did the model performed
inadequately in this patient population. They demonstrated a
trend toward a lower rate of deep vein thrombosis than
pulmonary embolism and hypothesize that in situ pulmonary
thrombosis, rather than embolus, may be a largely
unrecognized but significant phenomenon. They conclude
that a well designed prospective study is warranted.
Innovations
Two recently published papers describe novel approaches to
common clinical problems.
In an eloquent phase II study, Ichai and colleagues [8]
compared the use of hypertonic sodium lactate (HSL) with
mannitol for the treatment of intracranial hypertension after
severe traumatic brain injury. The trial used a randomized
design with rescue crossover. Thirty-four patients were
recruited. Those who received HSL, either initially or as rescue
therapy, had better short-term physiological outcomes. Five of
the 17 who received HSL first required mannitol rescue
therapy, as compared with eight of 17 in the mannitol group,
who received lactate rescue. One-year Glasgow Outcome
Scores were significantly better in the patients who received
HSL either as primary or rescue therapy, although the study
was too small for this difference to be regarded as reliable. A
phase III study of HSL is certainly justified on the basis of the
data presented, not least given the burden of death and
severe disability after traumatic brain injury and the
contradictory trial evidence surrounding all therapies, including
mannitol, hypertonic saline, mild therapeutic hypothermia and
decompressive craniectomy.
The second thought provoking innovation is reported by
Krouzecky and colleagues [9], who present their successful
implementation of cooling as a means of achieving effectiveanticoagulation in an extracorporeal renal replacement circuit.
They took 12 normal pigs and randomized half of them to the
cooled circuit and half to ‘isothermia’. They used an
arteriovenous system at 150 ml/minute with no pre-dilution. In
the cooled protocol the arterial side was reduced to 20°C
and the venous side re-warmed to 38°C. The cooling
technique was very successful in preserving the circuit for
6 hours and had no detrimental effects. Further trials with
prolonged exposure should be forthcoming.
Primum non nocere
Finally in this round up, yet another example has emerged of a
potentially dogma-busting study. Ristagno and colleagues
[10] have investigated the effects of cardiopulmonary
resuscitation with and without adrenaline (epinephrine) on
cerebral microvascular flow, tissue oxygenation and carbon
dioxide tension. In their pig study they investigated four
protocols. All groups had ventricular fibrillation induced with
no intervention for 3 minutes followed by standard
cardiopulmonary resuscitation. Group 1 received a placebo,
group 2 received adrenaline, group 3 received adrenaline
after pre-treatment with an α1 and β blocker, whereas group 4
received adrenaline after pre-treatment with an α2 and  β
blocker. The cerebral perfusion was adversely affected by the
adrenaline. This effect was prevented by α1 blockade. This
study raises many issues, most important of which is whether
adrenaline is the right drug to optimize cerebral and cardiac
perfusion after cardiac arrest. This is a difficult area to
investigate and, despite the many limitations, this study
should provoke considerable debate and further studies.
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